A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK

HDBuzz·May 7

This story is reported by HDBuzz. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again

BioSpace·Jun 17

2

UniQure to seek AMT-130 approval as FDA agrees on path for drug

huntingtonsdiseasenews.com·Jun 23

3

FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility

MedCity News·Jun 17

4

Flexibility restored? Uniqure plans for BLA filing in Huntington’s

BioWorld News·Jun 17

5

FDA says 3-year trial data can support Huntington’s treatment filing

Stock Titan·Jun 17

6

uniQure shares surge as FDA stance appears to reopen a near-term filing path for AMT-130

Quiver Quantitative·Jun 17

7

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

Yahoo Finance·Apr 30

8

After FDA demands full trial for AMT-130, uniQure pivots to UK regulatory pathway with Q3 2026 filing planned

eciks.org·Jun 17